Eli Lilly PE Ratio 2006-2019 | LLY

Current and historical p/e ratio for Eli Lilly (LLY) from 2006 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Eli Lilly PE ratio as of September 19, 2019 is 20.31.
Eli Lilly PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-09-20 116.16 14.57
2019-06-30 110.79 $7.97 13.90
2019-03-31 129.76 $6.28 20.66
2018-12-31 115.11 $3.13 36.77
2018-09-30 106.20 $0.45 235.99
2018-06-30 83.98 $-0.14 0.00
2018-03-31 75.62 $1.06 71.34
2017-12-31 81.96 $-0.20 0.00
2017-09-30 82.48 $2.11 39.09
2017-06-30 78.85 $2.31 34.14
2017-03-31 80.07 $2.07 38.68
2016-12-31 69.55 $2.58 26.96
2016-09-30 75.41 $2.30 32.79
2016-06-30 73.52 $2.32 31.69
2016-03-31 66.78 $2.17 30.78
2015-12-31 77.60 $2.26 34.34
2015-09-30 76.60 $2.21 34.66
2015-06-30 75.96 $1.93 39.36
2015-03-31 65.65 $2.05 32.02
2014-12-31 61.90 $2.23 27.76
2014-09-30 57.76 $2.50 23.11
2014-06-30 54.93 $3.14 17.49
2014-03-31 51.59 $3.57 14.45
2013-12-31 44.29 $4.31 10.28
2013-09-30 43.29 $4.38 9.88
2013-06-30 41.88 $4.45 9.41
2013-03-31 47.99 $4.17 11.51
2012-12-31 41.30 $3.66 11.28
2012-09-30 39.29 $3.69 10.65
2012-06-30 35.16 $3.62 9.71
2012-03-31 32.61 $3.86 8.45
2011-12-31 33.24 $3.90 8.52
2011-09-30 29.18 $4.18 6.98
2011-06-30 29.22 $4.25 6.87
2011-03-31 27.04 $4.40 6.14
2010-12-31 26.56 $4.58 5.80
2010-09-30 27.31 $4.36 6.26
2010-06-30 24.71 $4.04 6.12
2010-03-31 26.35 $3.88 6.79
2009-12-31 25.61 $3.95 6.48
2009-09-30 23.36 $-0.19 0.00
2009-06-30 24.14 $-1.48 0.00
2009-03-31 22.96 $-1.66 0.00
2008-12-31 27.31 $-1.89 0.00
2008-09-30 29.43 $2.20 13.38
2008-06-30 30.56 $3.48 8.78
2008-03-31 33.82 $3.21 10.54
2007-12-31 34.68 $2.71 12.80
2007-09-30 36.68 $2.05 17.89
2007-06-30 35.74 $2.00 17.87
2007-03-31 34.10 $2.15 15.86
2006-12-31 32.82 $2.45 13.40
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $108.824B $24.556B
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $344.174B 14.99
Roche Holding AG (RHHBY) Switzerland $241.683B 0.00
Merck (MRK) United States $212.562B 17.48
Pfizer (PFE) United States $201.220B 11.85
Novartis AG (NVS) Switzerland $197.737B 17.02
Novo Nordisk (NVO) Denmark $120.697B 21.33
AstraZeneca (AZN) United Kingdom $114.317B 22.12
Sanofi (SNY) France $111.209B 13.66
AbbVie (ABBV) United States $105.372B 8.44
GlaxoSmithKline (GSK) United Kingdom $102.412B 12.87
Bristol-Myers Squibb (BMY) United States $81.559B 11.57
Bayer (BAYRY) Germany $68.561B 9.99
H Lundbeck (HLUYY) Denmark $6.721B 9.70